CENTESSA PHARMACEUTICALS-ADR (CNTA)
US1523091007 - ADR
ChartMill assigns a Buy % Consensus number of 85% to CNTA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 13.87. This target is 54.65% above the current price.
CNTA was analyzed by 11 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about CNTA.
In the previous month the buy percentage consensus was at a similar level.
CNTA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-01 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-11-15 | Jefferies | Upgrade | Hold -> Buy |
| 2023-10-26 | Morgan Stanley | Upgrade | Underweight -> Equal-Weight |
| 2023-08-15 | SVB Securities | Maintains | Outperform -> Outperform |
| 2023-08-15 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-07-25 | BMO Capital | Maintains | Outperform -> Outperform |
| 2023-06-21 | Evercore ISI Group | Initiate | Outperform |
| 2023-06-12 | Guggenheim | Initiate | Buy |
| 2023-05-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-03-17 | SVB Leerink | Initiate | Outperform |
| 2023-01-24 | Morgan Stanley | Maintains | Underweight |
| 2022-08-12 | Morgan Stanley | Downgrade | Overweight -> Underweight |
| 2022-08-11 | BMO Capital | Maintains | Outperform |
| 2022-08-11 | Goldman Sachs | Maintains | Neutral |
| 2022-07-15 | Morgan Stanley | Maintains | Overweight |
| 2022-06-17 | BMO Capital | Initiate | Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2022-05-24 | Morgan Stanley | Maintains | Overweight |
| 2021-06-23 | Morgan Stanley | Initiate | Overweight |
| 2021-06-22 | Goldman Sachs | Initiate | Buy |
| 2021-06-22 | Morgan Stanley | Initiate | Overweight |
| 2021-06-22 | Jefferies | Initiate | Buy |